June 16 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
UNIT ENTERED INTO A LICENSE AGREEMENT WITH NEXTCURE
PURSUANT TO LICENSE AGREEMENT, GROUP ELIGIBLE TO RECEIVE PAYMENTS UP TO US$745 MILLION
UNDER DEAL NEXTCURE TO OBTAIN GLOBAL RIGHTS TO SIM0505 NOVEL ANTIBODY-DRUG CONJUGATE, OTHERS
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.